Pharmaceutical industry's perspective on health technology assessment
- 1 January 2004
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 20 (1) , 97-101
- https://doi.org/10.1017/s0266462304000868
Abstract
This article presents the pharmaceutical industry's perspective on health technology assessment (HTA) with specific comments on the HTA systems in England and Wales, France, The Netherlands, and Sweden. The comments are focused on the following main themes: (i) The contributions of the HTA system to overall efficiency in the health-care system, (ii) HTA as a cost-driver for industry, patients, government, and society, and (iii) The various implementation barriers that currently exist for a successful implementation of HTA results.Keywords
This publication has 16 references indexed in Scilit:
- Overview of health technology assessment in FranceInternational Journal of Technology Assessment in Health Care, 2004
- Technology assessment, priority setting, and appropriate care in Dutch health careInternational Journal of Technology Assessment in Health Care, 2004
- Health technology assessment and priority setting for health policy in SwedenInternational Journal of Technology Assessment in Health Care, 2004
- Use of Economic Evaluation in Decision Making: What Needs to Change?Value in Health, 2002
- National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working?PharmacoEconomics, 2002
- The Price Of Progress: Prescription Drugs In The Health Care MarketHealth Affairs, 2001
- Is Technological Change In Medicine Worth It?Health Affairs, 2001
- Effectiveness, efficiency, and NICEBMJ, 2001
- Research into the use of health economics in decision making in the United Kingdom—Phase IIHealth Policy, 1999
- Economic evaluation under managed competition: Evidence from the U.K.Social Science & Medicine, 1997